➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 9,895,380

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,895,380
Title:Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
Inventor(s): Andre; Patrice (Lyons, FR), Lotteau; Vincent (Lyons, FR), Radreau; Pauline (Lyons, FR), Gilardone; Marine (Millery, FR), Patin; Amaury (Lausanne, CH), Roche; Didier (Ecully, FR), Cravo; Daniel (Montesson, FR), Hallakou-Bozec; Sophie (Antony, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) EDELRIS (Lyons, FR) POXEL (Lyons, FR)
Application Number:14/917,958
Patent Claims:see list of patent claims

Details for Patent 9,895,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 2002-10-16 ⤷  Free Forever Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Pa 2033-09-11 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 2002-10-16 ⤷  Free Forever Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE CLAUDE BERNARD--LYON 1 (Villeurbanne, FR) ENS--ECOLE NORMALE SUPERIEURE DE LYON (Lyons, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Pa 2033-09-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,895,380

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2015036442 ⤷  Free Forever Trial
United States of America 10071108 ⤷  Free Forever Trial
United States of America 2016220586 ⤷  Free Forever Trial
United States of America 2018169115 ⤷  Free Forever Trial
Slovenia 3043865 ⤷  Free Forever Trial
Serbia 61540 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
Boehringer Ingelheim
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.